Vitiligo and skin cancer: is it a question of ethnicity?

Gran, Sonia

doi:10.1111/bjd.18533

Cited by 3 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As vitiligo often affects exposed acral areas such as the face and hands, NB‐UVB phototherapy is often used as part of a combined therapeutic strategy. However, the lack of information concerning the safety of long‐term UVB exposure, and the existence of conflicting data concerning the incidence of melanoma and non‐melanoma skin cancer in patients with vitiligo, may be a limiting factor of phototherapy 42,43 . Systemic therapies may benefit patients with unstable, widespread or recalcitrant vitiligo, 10 but it is important to remember that outcomes have varied widely and there is limited evidence supporting their use 44 .…”

Section: Discussionmentioning

confidence: 99%

“…However, the lack of information concerning the safety of long-term UVB exposure, and the existence of conflicting data concerning the incidence of melanoma and non-melanoma skin cancer in patients with vitiligo, may be a limiting factor of phototherapy. 42,43 Systemic therapies may benefit patients with unstable, widespread or recalcitrant vitiligo, 10 but it is important to remember that outcomes have varied widely and there is limited evidence supporting their use. 44 The use of systemic corticosteroids for up to 6 months is a first-line option only in the case of rapidly progressing disease.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Topical ruxolitinib: A new treatment for vitiligo

Tavoletti

Avallone

Conforti

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

Vitiligo is a chronic autoimmune skin disorder whose diagnosis is often psychologically upsetting. The efficacy of the available therapies, including topical corticosteroids and topical calcineurin inhibitors, has historically been limited and the management of vitiligo is still challenging. As vitiligo is a chronic disease limited to the skin, topical rather than systemic therapies may be preferable (especially among patients with localised lesions) to avoid the long‐term side‐effects of the latter. A topical formulation of ruxolitinib, a selective JAK1/2 inhibitor, has recently been approved in the United States for the treatment of non‐segmental vitiligo in patients aged >12 years based on data from the phase III TRuE‐V1 and TRuE‐V2 clinical trials. The aim of this review is to describe the current evidence concerning the efficacy and safety of topical ruxolitinib in the treatment of vitiligo, and discuss issues regarding its use in younger children and pregnant or breastfeeding women, as well as the duration and durability of treatment. The promising results obtained so far suggest that 1.5% ruxolitinib cream is an effective means of treating vitiligo.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Topical ruxolitinib: A new treatment for vitiligo

Tavoletti

Avallone

Conforti

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“… 18 How many chemists have programs focusing on lupus or vitiligo? 19 − 21 Finally, the poor representation of underrepresented minority (URM) faculty in academia results in little to no role models for students of color.…”

Section: Understanding the Scope Of The Problemmentioning

confidence: 99%

“…The implications are a serious limitation to the diversity of thought and a low probability that research efforts will address the needs of all segments of society . How many chemists have programs focusing on lupus or vitiligo? − Finally, the poor representation of underrepresented minority (URM) faculty in academia results in little to no role models for students of color.…”

Section: Understanding the Scope Of The Problemmentioning

confidence: 99%